# Siltuximab in Schizophrenia

> **NCT02796859** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Brian Miller** · enrollment: 30 (estimated)

## Conditions studied

- Schizophrenia
- Psychotic Disorders

## Interventions

- **DRUG:** Siltuximab
- **DRUG:** normal saline

## Key facts

- **NCT ID:** NCT02796859
- **Lead sponsor:** Brian Miller
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02796859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02796859, "Siltuximab in Schizophrenia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02796859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*